We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Diagnostic Technique Could Revolutionize Identification of Pathogens in Biological Samples

By LabMedica International staff writers
Posted on 26 Apr 2023

In cases where a patient suffers from an infection, particularly in their bloodstream, traditional methods can take up to seven days to identify pathogens. This delay impedes prompt and accurate diagnosis and treatment, negatively affecting the patient's prognosis. A similar lag occurs in cell therapy product manufacturing, where it can take seven to 14 days to detect contaminants like bacteria, viruses, and fungi. As cell therapy products cannot be sterilized, early contaminant detection is crucial to restart the production cycle, ensuring the safe and prompt delivery of these products to patients.

A research team from the Singapore-MIT Alliance for Research and Technology (SMART, Singapore) is developing an innovative diagnostic method capable of quickly identifying low-abundance pathogens in biological samples. In prior research, the team developed electrostatic microfiltration as an efficient sample preparation device for bacteria enrichment. Their current goal is to integrate this microfilter with mainstream detection methods, allowing for bacterial detection using digital loop-mediated isothermal amplification—a type of polymerase chain reaction (PCR). The resulting system will be fast, single-use, portable, and user-friendly, eliminating the need for a highly specialized facility. Additionally, it will be compatible with other advanced downstream detection techniques and can easily be incorporated into existing commercial kits or facilities to enhance detection method performance.

“This project builds on on-going projects at SMART focused on separating viruses and bacteria – which are much smaller than mammalian cells – from biological samples, and could revolutionize the way pathogens are identified,” said Dr. Yaoping Liu, Senior Postdoctoral Associate at SMART CAMP, who is leading the research team. “The use of an efficient and relatively cost-effective method could significantly improve the prognosis of sepsis and other infectious diseases, and allow the delivery of timely and more personalized care.”

Related Links:
SMART 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.